WO2009125295A3 - Genetic markers of mmp- 12 gene for wound development - Google Patents

Genetic markers of mmp- 12 gene for wound development Download PDF

Info

Publication number
WO2009125295A3
WO2009125295A3 PCT/IB2009/005371 IB2009005371W WO2009125295A3 WO 2009125295 A3 WO2009125295 A3 WO 2009125295A3 IB 2009005371 W IB2009005371 W IB 2009005371W WO 2009125295 A3 WO2009125295 A3 WO 2009125295A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
gene
genetic markers
wound development
wound
Prior art date
Application number
PCT/IB2009/005371
Other languages
French (fr)
Other versions
WO2009125295A2 (en
Inventor
Paolo Zamboni
Donato Gemmati
Original Assignee
Systagenix Wound Management Ip Co.B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systagenix Wound Management Ip Co.B.V. filed Critical Systagenix Wound Management Ip Co.B.V.
Publication of WO2009125295A2 publication Critical patent/WO2009125295A2/en
Publication of WO2009125295A3 publication Critical patent/WO2009125295A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

A method of diagnosis or prognosis of wound development, eg. ulcers, comprising the step of measuring in a sample of nucleic acid for the presence of a polymorphism consisting of an adenosine (A) to guanosine (G) substitution at position -82 in the MMP-12 gene promoter. Also provided are methods of diagnosis, prognosis and treatment, wound treatment systems and devices and kits for use in such methods.
PCT/IB2009/005371 2008-04-08 2009-04-07 Genetic markers of wound development WO2009125295A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0806369.5 2008-04-08
GB0806369A GB2459098A (en) 2008-04-08 2008-04-08 Genetic markers of wound development

Publications (2)

Publication Number Publication Date
WO2009125295A2 WO2009125295A2 (en) 2009-10-15
WO2009125295A3 true WO2009125295A3 (en) 2009-12-17

Family

ID=39433299

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/005371 WO2009125295A2 (en) 2008-04-08 2009-04-07 Genetic markers of wound development

Country Status (2)

Country Link
GB (1) GB2459098A (en)
WO (1) WO2009125295A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2336431A (en) * 1998-04-17 1999-10-20 Johnson & Johnson Medical Ltd Method of analysis of chronic ulcers
WO2002015893A2 (en) * 2000-08-21 2002-02-28 Pfizer Limited Treatment of wounds
WO2003002119A1 (en) * 2001-06-27 2003-01-09 Johnson & Johnson Medical Limited Treatment and prevention of lipodermatosclerosis
US20050079542A1 (en) * 2001-11-05 2005-04-14 Cullen Breda Mary Wound monitoring

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001257073A1 (en) * 2000-04-17 2001-10-30 Genaissance Pharmaceuticals, Inc. Haplotypes of the mmp3 gene
US20030087863A1 (en) * 2001-06-28 2003-05-08 Mount Sinai School Of Medicine Methods for diagnosing and treating a disease mediated by decreased MMP-2 function
US20030157110A1 (en) * 2002-01-07 2003-08-21 Millennium Pharmaceuticals, Inc. Methods for the treatment of metabolic disorders, including obesity and diabetes
KR20080011292A (en) * 2005-05-19 2008-02-01 시너젠즈 바이오사이언스 리미티드 Methods for the assessment of risk of developing lung cancer using analysis of genetic polymorphisms
CA2673092A1 (en) * 2006-12-19 2008-06-26 Synergenz Bioscience Limited Methods and compositions for the assessment of cardiovascular function and disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2336431A (en) * 1998-04-17 1999-10-20 Johnson & Johnson Medical Ltd Method of analysis of chronic ulcers
WO2002015893A2 (en) * 2000-08-21 2002-02-28 Pfizer Limited Treatment of wounds
WO2003002119A1 (en) * 2001-06-27 2003-01-09 Johnson & Johnson Medical Limited Treatment and prevention of lipodermatosclerosis
US20050079542A1 (en) * 2001-11-05 2005-04-14 Cullen Breda Mary Wound monitoring

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AJAY VIKRAM SINGH: "Micro-array project for diagnosis of vascular lesions under the topic Nanotechnology and nanoscience", September 2007 (2007-09-01), pages 1 - 14, XP002551076, Retrieved from the Internet <URL:air.unimi.it/bitstream/2434/64292/1/MIUR+Thesis+Report.doc> [retrieved on 20091019] *
HELLMIG STEPHAN ET AL: "Genetic variants in matrix metalloproteinase genes are associated with development of gastric ulcer in H. Pylori infection.", THE AMERICAN JOURNAL OF GASTROENTEROLOGY JAN 2006, vol. 101, no. 1, January 2006 (2006-01-01), pages 29 - 35, XP002551079, ISSN: 0002-9270 *
IMPOLA U ET AL: "Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds.", THE BRITISH JOURNAL OF DERMATOLOGY APR 2005, vol. 152, no. 4, April 2005 (2005-04-01), pages 720 - 726, XP002550625, ISSN: 0007-0963 *
SENGUPTA N ET AL: "The role of matrix metalloproteinases in stromal/epithelial interactions in the gut.", PHYSIOLOGY (BETHESDA, MD.) DEC 2007, vol. 22, December 2007 (2007-12-01), pages 401 - 409, XP002551078, ISSN: 1548-9213 *
SU LI ET AL: "Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer.", CARCINOGENESIS MAY 2006, vol. 27, no. 5, May 2006 (2006-05-01), pages 1024 - 1029, XP002550624, ISSN: 0143-3334 *

Also Published As

Publication number Publication date
GB0806369D0 (en) 2008-05-14
GB2459098A (en) 2009-10-14
WO2009125295A2 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
WO2012021795A3 (en) Pancreatic cancer biomarkers and uses thereof
WO2010062913A3 (en) Methods and systems for analysis of sequencing data
WO2011087760A3 (en) Processes and kits for identifying aneuploidy
WO2010026488A3 (en) Methods and kits for nucleic acid sequencing
WO2009092035A3 (en) Methods and compositions for the analysis of biological molecules
EP2224017A4 (en) Method for amplifying target nucleic acid sequence and probe used for the same
WO2010019414A3 (en) Detecting nucleic acid
WO2012024658A3 (en) Integrated analysis system
WO2007082099A3 (en) Gene expression markers for colorectal cancer prognosis
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
WO2007114947A3 (en) Highly sensitive system and methods for analysis of troponin
WO2009108918A3 (en) Methods and systems for social networking based on nucleic acid sequences
WO2012075506A3 (en) Methods for predicting and treating infection-induced illnesses and predicting the severity of infection-induced illnesses
WO2009060847A1 (en) Method and kit for preparation of sample for use in nucleic acid amplification
WO2010104893A3 (en) Methods for the determination of a copy number of a genomic sequence in a biological sample
WO2011153354A8 (en) Methods and kits for in situ detection of nucleotide sequences
WO2008128043A3 (en) Diagnostic and prognostic methods for renal cell carcinoma
EP2314680A4 (en) Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods
WO2011133949A3 (en) Genetic risk analysis in reward deficiency syndrome
WO2014005125A3 (en) Fluorescent compounds and uses thereof
WO2014018958A3 (en) Methods and devices for electromagnetic amplification of nucleic acids
WO2008107114A3 (en) Control genes for the normalization of gene expression analysis data
WO2013016712A3 (en) Methods for fixing and detecting rna
WO2012056227A3 (en) Multiplex amplification and detection
WO2013090386A3 (en) Methods and kits for room temperature in situ detection of a target nucleic acid in a biological sample

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: COMMUNICATION PURSUANT TO RULE 112(1) EPC (EPO-FORM 1205A OF 10.02.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09730587

Country of ref document: EP

Kind code of ref document: A2